Sai Parenterals IPO: GMP, Price Band, Date & Analysis

Sai Parenteral's IPO- Company Analysis

Sai Parenteral's IPO under the Mainboard IPO category is a bookbuild issue of Rs. 408.79 Cr by Sai Parenteral's Limited, and is a multifaceted pharmaceutical formulations company that specializes in production, research, and development.

Cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology are only a few of the therapeutic categories covered by the product range. Offerings include injectables, pills, capsules, liquid orals, and ointments, among other dosage forms.

In India, Sai Parenteral serves a broad range of clients, including pharmaceutical firms, public and private hospitals, mega stockists, and central and state government organizations.

Sai Parenteral's IPO Details

The Sai Parenteral's IPO date of opening is 24 Mar 2026, its initial public offering will end on 27 Mar, IPO allotment on Mar 30 and refund initiation on Apr 01, 2026.

The Rs. 408.79 crore new Mainboard IPO comprises a combination of fresh issue of 0.73 crore shares (₹285.00 crores) and offer for sale of 0.32 crore shares (₹123.79 crores).

The Sai Parenteral's IPO listing date (expected) might be on Thursday, April 02, 2026, and listing at the BSE and NSE. 

The Sai Parenteral's IPO price band is Rs. 372 to Rs. 392.

IPO Timetable (Tentative)

Industry Overview

Click to open demat account and apply for the IPO.

Company Financials

(Amount in Cr)

Cash Flows

(Amount in Mn)

Revenue Bifurcation

(Source: RHP)

The Objective of the Issue

The company desires to use the Net Proceeds from the Issue to fulfill its following goals:

• Capacity expansion and upgradation of manufacturing facilities. ~ Rs. 110.80 Cr.
• Establishment of a new R&D Centre. ~ Rs. 18.02 Cr.
• Repayment/prepayment of certain outstanding borrowings. ~ Rs. 14.30 Cr.
• Working capital requirements. ~ Rs. 33 Cr.
• Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia). ~ Rs. 35.64 Cr.
  
  

Listed Peers of Sai Parenteral's Ltd.

Valuation

Evaluation of P/E Ratio

Considering the period ended on FY 2025 with an EPS of Rs. 5.43 from the last year, the resulting P/E ratio is 72.19x.

Explore the Central Mine Planning & Design Institute IPO.

IPO's Strengths

• Player in a variety of generic formulations with a proven track record.
• Manufacturing facilities that are accredited and situated strategically.
• Strong emphasis on CDMO operations.
• A reputable distribution network both abroad and in India.
• Track record of acquisitions that add value.

IPO's Weaknesses

• Geographical concentration risk.
• Quality standard risks.
• Strict standards for quality compliance.
  
  

Sai Parenteral's IPO GMP (Grey Market Premium)

Sai Parenteral's IPO GMP today is Rs. 0 as of 19 Mar 2026 while writing this information. A price band set at Rs. 392 suggests that the estimated listing price of the IPO could be around Rs. 392, indicating a gain/loss of 0%

Sai Parenteral's IPO Summary

IPO Lot Details

Sai Parenteral's IPO Allotment Status

To check the Sai Parenteral's IPO Allotment Status, visit the official Registrar’s website or BSE website. Below are the website links for you.

Using BSE Website - ​BSE IPO allotment status

Promoters And Management of Sai Parenteral's Ltd.

• Anil Kumar Karusala
• Vijitha Gorrepati 
• Karusala Aruna
  
  

IPO Lead Managers

• Arihant Capital Markets Ltd. 
  
  

Dividend Policy

The company has not paid a dividend during the last three financial years.

Conclusion

With a wide range of products and robust R&D capabilities, Sai Parenteral's Limited IPO offers exposure to the expanding pharmaceutical and CDMO market.

The IPO looks pricey with a higher P/E value in comparison to peers, despite robust financial growth and return ratios. Before making a long-term investment, investors should balance growth potential against concerns, including geographic concentration and regulatory compliance.

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.

You must consult your financial advisor before making any financial decisions.

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.